Processing

Please wait...

Settings

Settings

1. WO2015187542 - HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Publication Number WO/2015/187542
Publication Date 10.12.2015
International Application No. PCT/US2015/033511
International Filing Date 01.06.2015
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42
Oxazoles
423
condensed with carbocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4245
Oxadiazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4709
Non-condensed quinolines containing further heterocyclic rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
containing two hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
A61K 31/423 (2006.01)
A61K 31/4245 (2006.01)
A61K 31/4709 (2006.01)
C07D 413/02 (2006.01)
C07D 417/02 (2006.01)
CPC
C07C 259/08
C07D 231/54
C07D 231/56
C07D 239/70
C07D 239/74
C07D 239/88
Applicants
  • CHDI FOUNDATION, INC. [US/US]; 350 Seventh Avenue, Suite 601 New York, NY 10001, US
Inventors
  • DOMINGUEZ, Celia; US
  • MUÑOZ-SANJUAN, Ignacio; US
  • LUCKHURST, Christopher, A.; GB
  • ALLEN, Daniel, R.; GB
  • RAPHY, Gilles; GB
  • BÛRLI, Roland, W.; GB
  • BRECCIA, Perla; GB
  • HAUGHAN, Alan, F.; GB
  • WISHART, Grant; GB
  • HUGHES, Samantha, J.; GB
  • JARVIS, Rebecca, E.; GB
  • VATER, Huw, D.; GB
  • PENROSE, Stephen, D.; GB
  • WALL, Michael; GB
  • STOTT, Andrew, J.; GB
  • SAVILLE-STONES, Elizabeth; GB
Agents
  • TANNER, Lorna L.; Sheppard Mullin Richter & Hampton LLP 379 Lytton Avenue Palo Alto, CA 94301, US
Priority Data
62/006,53402.06.2014US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF
(FR) INHIBITEURS D'HISTONE DÉSACÉTYLASE, ET COMPOSITIONS ET MÉTHODES D'UTILISATION DE CEUX-CI
Abstract
(EN)
Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein.
(FR)
L'invention concerne certains inhibiteurs d'histone désacétylase (HDAC) de formule I, des compositions de ceux-ci, et des méthodes d'utilisation de ceux-ci.
Latest bibliographic data on file with the International Bureau